Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?

por Bryant, Curtis, Mendenhall, Nancy P., Henderson, Randal H., Nichols, Romaine C., Mendenhall, William M., Morris, Christopher G., Williams, Christopher, Su, Zhong, Li, Zuofeng, Hoppe, Bradford S.
Publicado 2016

Circulating Cell-Free DNA Correlates with Body Integral Dose and Radiation Modality in Prostate Cancer

por Lockney, Natalie A., Henderson, Randal, Swarts, Steven G., Zhang, Zhenhuan, Zhang, Bingrong, Li, Jennifer, Zlotecki, Robert A., Morris, Christopher G., Casey-Sawicki, Katherine, Okunieff, Paul
Publicado 2020

Erectile Function, Incontinence, and Other Quality of Life Outcomes Following Proton Therapy for Prostate Cancer in Men 60 Years Old and Younger

por Hoppe, Bradford S, Nichols, Romaine C, Henderson, Randal H, Morris, Christopher G, Williams, Christopher R, Costa, Joseph, Marcus, Robert B, Mendenhall, William M, Li, Zuofeng, Mendenhall, Nancy P
Publicado 2012

Measuring Radiation Toxicity Using Circulating Cell-Free DNA in Prostate Cancer Patients

por Lockney, Natalie A., Henderson, Randal H., Swarts, Steven G., Zhang, Zhenhuan, Zhang, Bingrong, Li, Jennifer, Zlotecki, Robert A., Morris, Christopher G., Casey-Sawicki, Katherine A., Okunieff, Paul G.
Publicado 2021

Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials

por Henderson, Randal H., Hoppe, Bradford S., Marcus, Robert B., Mendenhall, William M., Nichols, R. Charles, Li, Zuofeng, Su, Zhong, Morris, Christopher G., Williams, Christopher R., Costa, Joseph, Mendenhall, Nancy P.
Publicado 2013

Insurance Approval for Definitive Proton Therapy for Prostate Cancer

por Mendenhall, William M., Brooks, Eric D., Smith, Stephanie, Morris, Christopher G., Bryant, Curtis B., Henderson, Randal H., Nichols, Romaine C., McIntyre, Kathy, Klein, Stuart L., Mendenhall, Nancy P.
Publicado 2021

Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression

por Kil, Whoon Jong, Nichols, Romaine C., Hoppe, Bradford S., Morris, Christopher G., Marcus, Robert B., Mendenhall, William, Mendenhall, Nancy P., Li, Zuofeng, Costa, Joseph A., Williams, Christopher R., Henderson, Randal H.
Publicado 2013

Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy

por Kharod, Shivam M., Mercado, Catherine E., Morris, Christopher G., Bryant, Curtis M., Mendenhall, Nancy P., Mendenhall, William M., Nichols, R. Charles, Hoppe, Bradford S., Liang, Xiaoying, Su, Zhong, Li, Zuofeng, Henderson, Randal H.
Publicado 2021

Image-Guided Hypofractionated Proton Therapy in Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Study

por Kharod, Shivam M., Nichols, R. Charles, Henderson, Randal H., Morris, Christopher G., Pham, Dat C., Seeram, Vandana K., Jones, Lisa M., Antonio-Miranda, Maria, Siragusa, Daniel A., Li, Zuofeng, Flampouri, Stella, Hoppe, Bradford S.
Publicado 2020

Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes

por Rutenberg, Michael S., Hoppe, Bradford S., Starr, Jason S., Awad, Ziad, Thomas, Mathew, Morris, Christopher G., Johnson, Perry, Henderson, Randal H., Jones, Jeremy C., Gharia, Bharatsinh, Bowers, Steven, Wolfsen, Herbert C., Krishnan, Sunil, Ko, Stephen J., Babiker, Hani M., Nichols, Romaine C.
Publicado 2022

Consensus Statement on Proton Therapy for Prostate Cancer

por Bryant, Curtis M., Henderson, Randal H., Nichols, R. Charles, Mendenhall, William M., Hoppe, Bradford S., Vargas, Carlos E., Daniels, Thomas B., Choo, C. Richard, Parikh, Rahul R., Giap, Huan, Slater, Jerry D., Vapiwala, Neha, Barrett, William, Nanda, Akash, Mishra, Mark V., Choi, Seungtaek, Liao, Jay J., Mendenhall, Nancy P.
Publicado 2021